Company news

Medexus Pharmaceuticals Inc. news in 2023

Medexus Pharmaceuticals Inc.'s news releases, calls and decks from 2023, newest first.

View company

Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million

November 8, 2023

Medexus Schedules Second Fiscal Quarter 2024 Conference Call

November 1, 2023

Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering

October 17, 2023

Medexus Fully Repays Convertible Debentures In Cash At Maturity

October 16, 2023

Medexus Announces Closing of C$10 Million Bought-Deal Public Offering

October 6, 2023

Medexus and medac Agree to Amend US Treosulfan Agreement

September 28, 2023

Medexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility

September 5, 2023

Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B

August 17, 2023

Medexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million

August 9, 2023

Medexus to Participate in Fireside Chat at SHARE Series Event

August 4, 2023

Medexus Schedules First Fiscal Quarter 2024 Conference Call

August 2, 2023

Medexus Announces Preliminary Revenue for Fiscal Q1 2024

July 12, 2023

Medexus Generates Record Revenue of Us$108.1 Million in Fiscal Year 2023

June 21, 2023

FDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric Patients

June 15, 2023

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2023 Conference Call

June 14, 2023

Medexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023

June 13, 2023

Medexus to Participate in the LD Micro Invitational XIII

June 1, 2023

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible Debentures

May 10, 2023

Medexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade Glioma

May 9, 2023

Calls in 2023